Aspire Biopharma Holdings (ASBP) Operating Expenses (2021 - 2026)

Aspire Biopharma Holdings (ASBP) has 6 years of Operating Expenses data on file, last reported at $1.7 million in Q1 2026.

• On a quarterly basis, Operating Expenses fell 89.38% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $5.4 million, a 67.06% decrease from a year earlier, with the FY2025 full-year figure at $19.4 million, up 1498.12% from the prior year.
• Operating Expenses for Q1 2026 stood at $1.7 million, down from $1.8 million in the prior quarter.
• Over the last five years, Operating Expenses for ASBP reached as high as $15.6 million in Q1 2025 and fell as low as $96923.0 in Q2 2024.
• Historically, Operating Expenses has averaged $1.4 million across 5 years, with a median of $324565.0 in 2023.
• Across the five-year window, Operating Expenses jumped 41493.38% in 2022 and sank 89.38% in 2026, its largest moves.
• Year by year, Operating Expenses stood at $314030.0 in 2022, then advanced by 28.21% to $402615.0 in 2023, then jumped by 65.85% to $667722.0 in 2024, then surged by 176.83% to $1.8 million in 2025, then decreased by 10.63% to $1.7 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $1.7 million in Q1 2026, $1.8 million in Q4 2025, and $1.1 million in Q3 2025.